Cybin Inc (CYBN) Stock Price, Quote & News

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical...

Industry: Biotechnology

Sector: Healthcare

Website: cybin.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

HedgeAlerts Nov. 15 at 10:38 PM

Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · NOV 21, 2025 Exp Entry Price: $0.10 - $0.15 Exit Price Target: $0.18 Profit Margin: +83% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

LiquidThetaOptions Nov. 15 at 10:10 PM

💎 LiquidTheta® Live Actionable Trade Asset: $CYBN Contracts: $CYBN May 15, 2026 $8 Calls Scale in: $2.10- $2.57 Scale out: $8.18-$14.02 Profit Potential : 156% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

HughJasol Nov. 15 at 8:44 PM

$CYBN the only way this gets to 55 is when the next reverse split happens… and they take ALL your shares… ridiculous company.

0 · Reply

LiquidThetaOptions Nov. 14 at 9:53 PM

💎 LiquidTheta® Live Actionable Trade Asset: $CYBN Contracts: $CYBN May 15, 2026 $8 Calls Scale in: $1.83- $2.24 Scale out: $7.13-$12.23 Profit Potential : 176% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

firetypecracker Nov. 14 at 9:49 PM

$CYBN Analysts’ Top Healthcare Picks: Serina Therapeutics (SER), Cybin ($CYBN ) https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-serina-therapeutics-ser-cybin-cybn-blurbs

0 · Reply

firetypecracker Nov. 14 at 9:44 PM

$CYBN NEWS TODAY - NOVEMBER 14, 2025: Analysts’ Top Healthcare Picks: Cybin (CYBN) In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Cybin, with a price target of $55.00. The company’s shares closed last Friday at $6.02. According to tipranks.com, Trucchio is a top 100 analyst with an average return of 34.8% and a 52.3% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Arrowhead Pharmaceuticals, and Alto Neuroscience, Inc. The word on The Street generally suggests a Strong Buy analyst consensus rating for Cybin, with an average price target of $47.00 https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-serina-therapeutics-ser-cybin-cybn-blurbs

0 · Reply

JarvisFlow Nov. 14 at 6:59 PM

HC Wainwright & Co. updates rating for Cybin ( $CYBN ) to Buy, target set at 150 → 55.

1 · Reply

HedgeAlerts Nov. 14 at 6:21 PM

Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · NOV 21, 2025 Exp Entry Price: $0.05 - $0.10 Exit Price Target: $0.18 Profit Margin: +82% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Rico_Again_Jorge Nov. 14 at 6:07 PM

$CYBN Not even a dumpster fire right now

0 · Reply

TimRegan_WTR Nov. 14 at 3:25 PM

$CYBN $MNMD $CMPS $GHRS

0 · Reply

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 7:20 AM EST - 2 days ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:30 AM EST - 3 days ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:30 AM EST - 9 days ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 5, 2025, 7:30 AM EST - 10 days ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:30 AM EST - 12 days ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Oct 31, 2025, 4:19 PM EDT - 15 days ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 18 days ago

Cybin Announces $175 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 25 days ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Sep 23, 2025, 5:00 PM EDT - 7 weeks ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 11, 2025, 3:59 PM EDT - 2 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 7:30 AM EDT - 2 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 4, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 2 months ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 2 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 3 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 13, 2025, 5:30 PM EDT - 3 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 7, 2025, 7:30 AM EDT - 3 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 17, 2025, 7:30 AM EDT - 4 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 1, 2025, 11:19 AM EDT - 4 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 10:03 PM EDT - 4 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 9:27 PM EDT - 4 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 13, 2025, 7:45 AM EDT - 5 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 12, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 11, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 3, 2025, 7:30 AM EDT - 5 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

May 22, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 20, 2025, 7:30 AM EDT - 6 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 15, 2025, 7:30 AM EDT - 6 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 14, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 8, 2025, 7:30 AM EDT - 6 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 1, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Apr 23, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 21, 2025, 8:00 AM EDT - 7 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Feb 10, 2025, 9:48 PM EST - 9 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Jan 15, 2025, 12:07 PM EST - 10 months ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 13, 2025, 7:30 AM EST - 10 months ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 9, 2025, 5:00 PM EST - 11 months ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 10, 2024, 7:30 AM EST - 1 year ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 4, 2024, 7:30 AM EST - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Nov 18, 2024, 7:00 AM EST - 1 year ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 14, 2024, 7:30 AM EST - 1 year ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

HedgeAlerts Nov. 15 at 10:38 PM

0 · Reply

LiquidThetaOptions Nov. 15 at 10:10 PM

0 · Reply

HughJasol Nov. 15 at 8:44 PM

$CYBN the only way this gets to 55 is when the next reverse split happens… and they take ALL your shares… ridiculous company.

0 · Reply

LiquidThetaOptions Nov. 14 at 9:53 PM

0 · Reply

firetypecracker Nov. 14 at 9:49 PM

$CYBN Analysts’ Top Healthcare Picks: Serina Therapeutics (SER), Cybin ($CYBN ) https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-serina-therapeutics-ser-cybin-cybn-blurbs

0 · Reply

firetypecracker Nov. 14 at 9:44 PM

0 · Reply

JarvisFlow Nov. 14 at 6:59 PM

HC Wainwright & Co. updates rating for Cybin ( $CYBN ) to Buy, target set at 150 → 55.

1 · Reply

HedgeAlerts Nov. 14 at 6:21 PM

0 · Reply

Rico_Again_Jorge Nov. 14 at 6:07 PM

$CYBN Not even a dumpster fire right now

0 · Reply

TimRegan_WTR Nov. 14 at 3:25 PM

$CYBN $MNMD $CMPS $GHRS

0 · Reply

Pangr444 Nov. 14 at 11:03 AM

$CYBN interesting take from the conference call. the high trail convertble was already converted in the amount of 30 million i.e. about 5 million shares or 10% of outstanding so only 20 mil cash was paid. why is that? and what happened to these shares? if high trail kept them it will show up soon as they own now 10% of the company. and also means they where in a hurry to keep the stake which is the max they could under the convertible agreement (no shareholder with more than 10%). If they sold them to lock in the 10% dividend that would explain the pressure on the price recently

0 · Reply

research_WTR Nov. 14 at 10:28 AM

In our latest WTR Healthcare Happenings Flashcast, hosts Tim Gerdeman and Robert Sassoon break down the latest developments shaping the therapeutic psychedelics investment landscape. 🔹 October’s fundraising surge marks the strongest quarter since 2021, signaling renewed investor confidence 🔹 Sector shifts from hype-driven speculation to data-backed optimism and late-stage clinical progress 🔹 Discussion of valuation trends, capital flows, and sustainability of momentum into 2026 🔹 How pharma partnerships and clinical validation are reshaping the narrative for psychedelic medicine Tune in now for expert insights on the sector’s next growth phase. Podcast Platforms: https://pod.link/1795488592 Website: https://www.watertowerresearch.com/media-detail/2764/Media #Psychedelics #HealthcareInvesting #MentalHealth #Biotech #LifeSciences #WTRHealthcareHappenings $CYBN $MNMD $CMPS $GHRS $MDMA

0 · Reply

HedgeAlerts Nov. 14 at 7:41 AM

Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · NOV 21, 2025 Exp Entry Price: $0.10 - $0.10 Exit Price Target: $0.18 Profit Margin: +84% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

firetypecracker Nov. 13 at 8:42 PM

$CYBN Eric So, Interim CEO speaks: “The participation of notable institutional investors underscores confidence in the strength of our science, the potential and differentiation of our therapeutic candidates, and our team’s proven ability to execute. This financing enables us to maintain strong momentum as we advance our Phase 2 and Phase 3 clinical trials toward key data readouts in 2026 and work to deliver meaningful clinical outcomes and potentially transformative therapies closer to patients in need. Across the organization we are focused on a disciplined execution strategy and building a strong foundation leading up to critical clinical milestones in 2026. Coupled with our clinical progress, scientific rigor, dominant IP, measured approach to capital deployment, and leadership continuity, Cybin ($CYBN ) is well positioned to advance towards our upcoming data readouts and beyond.” https://www.tipranks.com/news/the-fly/cybin-reports-q2-eps-1-39-consensus-1-33-thefly

0 · Reply

Rico_Again_Jorge Nov. 13 at 5:21 PM

$CYBN Garbage as usual

0 · Reply

BobJohnBuoy666 Nov. 13 at 4:48 PM

$CYBN would love a close at or above 6.05

0 · Reply

grumpygoose Nov. 13 at 4:39 PM

$CYBN All time lows on deck? Probably Can't blame Doug anymore

0 · Reply

ChristopherMcC Nov. 13 at 4:17 PM

$CYBN dumped. will be interesting the see the size of P72's position next reporting period.

1 · Reply

PsychedStocks Nov. 13 at 4:01 PM

$CMPS $CYBN $MNMD keep being patient. 2026 will be big for the whole sector

1 · Reply

kev90123 Nov. 13 at 3:01 PM

$CYBN

0 · Reply

ChristopherMcC Nov. 12 at 7:01 PM

$CYBN @TimRegan_WTR @research_WTR I know Cybin is a client, but what's Sassoon's take on Cybin being such a bust in comp to near peers? They're willing to note it, just not note why?

1 · Reply

TimRegan_WTR Nov. 12 at 5:44 PM

$CYBN $MNMD $CMPS

0 · Reply

Market Cap	149.37M
Revenue (ttm)	0.00
Net Income (ttm)	-81.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	461,800
Avg Vol	853,836
Day's Range	N/A - N/A
Shares Out	25.19M
Stochastic %K	11%
Beta	0.66
Analysts	Strong Sell
Price Target	$80.60